Sharyn BAKER  SITE

  • J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1179:122882. Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma. Garrison DA, Jin Y, Uddin ME, Sparreboom A, Baker SD. PubMed
  • Proc Natl Acad Sci U S A. 2021;118:e2020168118. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. PubMed
  • Pharmaceutics. 2020;12:E856. Role of OATP1B1 and OATP1B3 in Drug-Drug interactions mediated by Tyrosine Kinase Inhibitors. Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SD. PubMed
  • Clin Transl Sci. 2020;In press. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. Buelow DR, Anderson JT, Pounds SB, Shi L, Lamba JK, Hu S, Gibson AA, Goodwin EA, Sparreboom A, Baker SD. PubMed
  • Pharmaceutics. 2020;12:E788. Influence of Probenecid on the pharmacokinetics and pharmacodynamics of Sorafenib. Hussaarts KGAM, van Doorn L, Eechoute K, Damman J, Fu Q, van Doorn N, Eisenmann ED, Gibson AA, Oomen-de Hoop E, de Bruijn P, Baker SD, Koolen SLW, van Gelder T, van Leeuwen RWF, Mathijssen RHJ, Sparreboom A, Bins S. PubMed
  • Drug Metab Dispos. 2020;48:419-425. A. Role of OATP2B1 in drug absorption and drug-drug interactions. Chen M, Hu S, Li Y, Gibson AA, Fu Q, Baker SD, Sparreboom. PubMed
  • Pharmacol Res Perspect. 2019;7:e00534. Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice. Anderson JT, Hu S, Fu Q, Baker SD, Sparreboom A. PubMed
  • Clin Cancer Res. 2019;25:7320-7330. Sorafenib population pharmacokinetics and skin toxicities in children and adolescents with refractory/relapsed Leukemia or Solid Tumor Malignancies. Inaba H, Panetta JC, Pounds SB, Wang L, Li L, Navid F, Federico SM, Eisenmann ED, Vasilyeva A, Wang YD, Shurtleff S, Pui CH, Gruber TA, Ribeiro RC, Rubnitz JE, Baker SD. PubMed
  • Clin Pharmacol Ther. 2019;In press. Sorafenib activity and disposition in liver cancer does not depend on Organic Cation Transporter 1. Chen M, Neul C, Schaeffeler E, Frisch F, Winter S, Schwab M, Koepsell H, Hu S, Laufer S, Baker SD, Sparreboom A, Nies AT. PubMed
  • Clin Transl Sci. 2019;12:400-407. Interaction between sex and Organic Anion-Transporting Polypeptide 1b2 on the pharmacokinetics of Regorafenib and its metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in mice. Fu Q, Chen M, Anderson JT, Sun X, Hu S, Sparreboom A, Baker SD. PubMed
  • J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1090:43-51. Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. Fu Q, Chen M, Hu S, McElroy CA, Mathijssen RH, Sparreboom A, Baker SD. PubMed
  • Clin Pharmacol Ther. 2017;102:726-730. Kinase inhibitors: the reality behind the success. Jeon JY, Sparreboom A1, Baker SD. PubMed
  • Clin Transl Sci. 2017;10:271-279. Influence of OATP1B1 function on the disposition of Sorafenib-β-D-Glucuronide. Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD. PubMed
  • Clin Transl Sci. 2017 Sep;10:412-420. Identification of OAT1/OAT3 as contributors to Cisplatin toxicity. Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens J, Baker SD, Pabla N, Sparreboom A. PubMed
  • Cancer Res. 2017;77:2102-2111. OCTN1 Is a high-affinity carrier of nucleoside analogues.Drenberg CD, Gibson AA, Pounds SB, Shi L, Rhinehart DP, Li L3 Hu S, Du G, Nies AT, Schwab M, Pabla N, Blum W, Gruber TA, Baker SD, Sparreboom A. PubMed
  • Cancer Chemother Pharmacol. 2016;77:1039-52. Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. Edginton AN, Zimmerman EI, Vasilyeva A, Baker SD, Panetta JC. PubMed
  • Nat Commun. 2016 Mar 16;7:10880. A phosphotyrosine switch regulates organic cation transporters. Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L5, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N. PubMed
  • Clin Transl Sci. 2016;9:51-9. ABCC4 is a determinant of Cytarabine-induced cytotoxicity and myelosuppression. Drenberg CD, Hu S, Li L, Buelow DR, Orwick SJ, Gibson AA, Schuetz JD, Sparreboom A, Baker SD. PubMed
  • Cancer Res. 2016;76:117-26. Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death. Zimmerman EI, Gibson AA, Hu S, Vasilyeva A, Orwick SJ, Du G, Mascara GP, Ong SS, Chen T, Vogel P, Inaba H, Maitland ML, Sparreboom A, Baker SD. PubMed
  • Clin Pharmacol Ther. 2016;99:651-60. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD. PubMed
  • Clin Pharmacol Ther. 2015;98:266-87. Human ontogeny of drug transporters: review and recommendations of the Pediatric Transporter Working Group. Brouwer KL, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, Meibohm B, Nigam SK, Rieder M, de Wildt SN; Pediatric Transporter Working Group. PubMed
  • Cancer Res. 2015;75:2729-36. Hepatocellular shuttling and recirculation of Sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b. Vasilyeva A, Durmus S, Li L, Wagenaar E, Hu S, Gibson AA, Panetta JC, Mani S, Sparreboom A, Baker SD, Schinkel AH. PubMed
  • Br J Cancer. 2014;110:894-8. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A. PubMed
  • Clin Cancer Res. 2014;20:985-94. Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Nies AT1, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M, Pott C, Hofmann U, Volk C, Hu S, Baker SD, Sparreboom A, Ruth P, Koepsell H, Schwab M. PubMed
  • Clin Cancer Res. 2013;19:4359-4370. Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. Furmanski BD, Hu S, Fujita KI, Li L, Gibson AA, Janke LJ, Williams RT, Schuetz JD, Sparreboom A, Baker SD. PubMed
  • Clin Cancer Res. 2013;19:1458-66. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A, Baker SD. PubMed
  • Clin Pharmacol Ther. 2012;92:642-50. OATP1B1 polymorphism as a determinant of erythromycin disposition. Lancaster CS, Bruun GH, Peer CJ, Mikkelsen TS, Corydon TJ, Gibson AA, Hu S, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A. PubMed
  • Clin Cancer Res. 2012;18:4433-40. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A. PubMed
  • Mol Cancer Ther. 2012;11:921-9. Inhibition of OCTN2-mediated transport of carnitine by etoposide. Hu C, Lancaster CS, Zuo Z, Hu S, Chen Z, Rubnitz JE, Baker SD, Sparreboom A. PubMed
  • Clin Pharmacol Ther. 2011;89:693-701.  Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Franke RM, Lancaster CS, Peer CJ, Gibson AA, Kosloske AM, Orwick SJ, Mathijssen RH, Figg WD, Baker SD, Sparreboom A. PubMed
  • Clin Cancer Res. 2009;15:6062-9. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD. PubMed
  • Clin Pharmacol Ther. 2008;84:704-9. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, Sparreboom A. PubMed
  • Clin Pharmacol Ther. 2009;85:155-63. Pharmacogenetic pathway analysis of docetaxel elimination. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. PubMed
  • Clin Cancer Res. 2008;14:3141-8. Interaction of imatinib with human organic ion carriers. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A. PubMed
  • Cancer Biol Ther. 2007;6:432-8. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD. PubMed
  • Clin Pharmacol Ther. 2006;80:192-201. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K. PubMed

PubMed

Columbus, United States

BAKER SHARYN.jpg

Last update: October 2021